Targeting mir130b-IL-33-PD-L1 axis effectively inhibits esophageal squamous carcinoma progression

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Interleukin-33 (IL-33) and programmed death-ligand 1 (PD-L1) are implicated in cancer progression.
• The precise mechanisms linking IL-33 to PD-L1 expression in esophageal squamous cell carcinoma (ESCC) remain unclear.

Purpose of the Study:

• To elucidate the mechanistic basis of IL-33-induced PD-L1 upregulation in ESCC.
• To investigate the role of IL-33 and PD-L1 in ESCC progression and identify potential therapeutic targets.

Main Methods:

• Integrated multi-omics analyses and clinical datasets.
• In vitro studies using ESCC cell lines (qPCR, functional assays, dual-luciferase reporter assays).
• In vivo xenograft models and immunohistochemical analysis.

Main Results:

• Increased IL-33 and PD-L1 expression correlated with advanced ESCC stage and poor prognosis.
• IL-33 promoted ESCC cell migration, invasion, and proliferation, partly reversed by PD-L1 inhibition.
• MicroRNA-130b-3p suppressed ESCC progression by downregulating RUNX3, a transcriptional activator of IL-33, thereby reducing IL-33 and PD-L1 levels.

Conclusions:

• IL-33 is a key driver of PD-L1 expression and ESCC progression.
• MicroRNA-130b-3p acts as a tumor suppressor by inhibiting the IL-33/PD-L1 axis.
• IL-33 is an independent prognostic marker for ESCC, suggesting dual-targeted therapies.